Citius Pharmaceuticals stock reports USD 7.1 million LYMPHIR revenue

Citius Pharmaceuticals stock is tied to a commercial ramp that generated USD 7.1 million in LYMPHIR revenue in less than nine months. The figure comes from a Quartr summary dated September 15, 2026, which also described the early adoption of the oncology drug.

LYMPHIR builds commercial reach

The same Quartr summary put the number of adopting institutions at 44 and the number of health plans at 135. It reported a 77 percent gross margin for LYMPHIR, giving investors a concrete measure of product economics during the launch phase.

Citius Pharmaceuticals owns 62 percent of Citius Oncology, the subsidiary commercializing LYMPHIR, according to a PR Newswire release dated September 3, 2026. The company said the initial market for the therapy exceeds USD 400 million and described Mino-Lok and Halo-Lido as additional late-stage pipeline assets.

Analyst target stays far higher

Investing.com lists H.C. Wainwright with a Buy rating and a USD 4.00 12-month price target dated August 19, 2026. That target is USD 3.47 above the latest Nasdaq price of USD 0.53, a gap of 654.72 percent based on the two quoted values.

The operating story therefore depends on converting institutional access into repeat demand while the company funds development of its broader pipeline. The reported revenue and 77 percent margin offer measurable commercial progress, while the valuation remains exposed to the gap between early sales and the scale required for sustained profitability.

Nasdaq snapshot and valuation

Citius Pharmaceuticals was last at USD 0.53 on Nasdaq on September 30, 2026 at 4:00 p.m. ET, versus a previous close of USD 0.55. Its market capitalization was USD 14.6 million, and the 52-week range was USD 0.47 to USD 2.19, placing the latest price USD 1.66 below the yearly high.